---
_schema: default
id: 166293
date: 2025-01-30
title: Which protein markers are significant in the diagnosis of leukemia?
article_title: Which protein markers are significant in the diagnosis of leukemia?
date_format: MMM DD, YYYY
post_on_text: Posted on
seo:
  title: QuickTakes | Health studies
  page_description: >-
    This content discusses significant protein markers used in the diagnosis of leukemia, including CD markers, PML-RARα fusion protein, FLT3 mutations, BCR-ABL fusion protein, and LDH, highlighting their roles in classifying leukemia types and guiding treatment.
  page_keywords: >-
    leukemia, protein markers, diagnosis, CD markers, PML-RARα, FLT3 mutations, BCR-ABL fusion protein, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, LDH, biomarkers, cancer, flow cytometry, treatment response, prognosis
author: QuickTakes
question: >-
    Which protein markers are significant in the diagnosis of leukemia?
answer: >-
    In the diagnosis of leukemia, several protein markers play a significant role. These markers are crucial for classifying the disease, monitoring treatment responses, and predicting outcomes. Here are some notable protein markers associated with different types of leukemia:\n\n1. **CD Markers**: Flow cytometry is commonly used to identify specific cell surface proteins (CD markers) that help distinguish leukemia cells from normal hematopoietic cells. For example:\n   - **CD19** and **CD10** are often expressed in acute lymphoblastic leukemia (ALL).\n   - **CD5** and **CD23** are typically found in chronic lymphocytic leukemia (CLL).\n\n2. **PML-RARα Fusion Protein**: This protein is found in approximately 90% of acute promyelocytic leukemia (APL) cases. It results from a fusion between the promyelocyte leukemia (PML) gene and the retinoic acid receptor alpha (RARA) gene, playing a critical role in the pathogenesis of APL.\n\n3. **FLT3 Mutations**: In acute myeloid leukemia (AML), mutations in the FLT3 gene are significant. These mutations can serve as prognostic markers and are often tested in newly diagnosed AML patients.\n\n4. **BCR-ABL Fusion Protein**: This protein is associated with chronic myelogenous leukemia (CML) and results from a translocation between chromosomes 9 and 22, leading to the Philadelphia chromosome. The presence of this fusion protein is critical for diagnosis and treatment planning.\n\n5. **LDH (Lactate Dehydrogenase)**: Elevated levels of LDH can indicate the presence of various cancers, including leukemia. It is often used as a marker for tumor burden and prognosis.\n\n6. **Other Biomarkers**: Recent studies have focused on identifying novel biomarkers through proteomic profiling, which can provide insights into the diagnosis and prognosis of leukemia. These include various differentially expressed proteins that may serve as potential biomarkers.\n\nThe identification and application of these protein markers are essential for improving the accuracy of leukemia diagnoses and tailoring treatment strategies to individual patients. As research continues, new markers may emerge, enhancing our understanding and management of leukemia.
subject: Health studies
file_name: which-protein-markers-are-significant-in-the-diagnosis-of-leukemia.md
url: /learn/health-studies/questions/which-protein-markers-are-significant-in-the-diagnosis-of-leukemia
---

&nbsp;